Monoamine oxidase A: An emerging therapeutic target in prostate cancer
Monoamine oxidase A (MAOA), a mitochondrial enzyme degrading biogenic and dietary amines, has been studied in the contexts of neuropsychiatry and neurological disorders for decades, but its importance in oncology, as best exemplified in prostate cancer (PC) to date, was only realized recently. PC is...
Main Authors: | Chia-Hui Chen, Boyang Jason Wu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-02-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1137050/full |
Similar Items
-
Association of Monoamine Oxidase A with Tumor Burden and Castration Resistance in Prostate Cancer
by: Meenakshi Meenu, MBBS, MD, DM, et al.
Published: (2020-01-01) -
Monoamine Oxidase (MAO) as a Potential Target for Anticancer Drug Design and Development
by: Reem Aljanabi, et al.
Published: (2021-10-01) -
Strategies to Re-Sensitize Castration-Resistant Prostate Cancer to Antiandrogen Therapy
by: Belén Congregado Ruiz, et al.
Published: (2023-04-01) -
Role of Monoamine Oxidase Activity in Alzheimer’s Disease: An Insight into the Therapeutic Potential of Inhibitors
by: Tapan Behl, et al.
Published: (2021-06-01) -
Prior switching to a second-line nonsteroidal antiandrogen does not impact the therapeutic efficacy of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world retrospective study
by: Jin-Ge Zhao, et al.
Published: (2018-01-01)